Orchid Pharma Limited - Laporan Laba Rugi (TTM)

Orchid Pharma Limited
IN ˙ NSEI
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Orchid Pharma Limited menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 4,687 4,420 4,501 4,232 4,424 5,010 5,596 5,982 6,357 6,341 6,659 7,178 7,513 8,122 8,194 8,809 9,048 9,015 9,219 8,504
Change (%) -5.69 1.82 -5.97 4.53 13.24 11.69 6.91 6.27 -0.25 5.01 7.80 4.67 8.10 0.89 7.50 2.72 -0.36 2.26 -7.75
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 2,122 2,197 2,413 2,380 2,699 3,027 3,271 3,491 3,781 3,813 4,013 4,435 4,655 4,919 5,032 5,414 5,502 5,531 5,672 4,928
Change (%) 3.57 9.81 -1.36 13.37 12.16 8.07 6.72 8.31 0.84 5.24 10.53 4.96 5.66 2.30 7.59 1.63 0.52 2.55 -13.11
% of Revenue 45.27 49.71 53.62 56.24 61.00 60.41 58.46 58.35 59.47 60.12 60.26 61.79 61.96 60.56 61.41 61.46 60.81 61.34 61.52 57.95
Gross Operating Profit 2,565 2,223 2,088 1,852 1,725 1,983 2,325 2,492 2,577 2,529 2,646 2,743 2,858 3,203 3,162 3,395 3,546 3,485 3,548 3,576
Change (%) -13.35 -6.08 -11.29 -6.83 14.95 17.22 7.18 3.41 -1.86 4.66 3.65 4.19 12.07 -1.28 7.37 4.45 -1.72 1.80 0.80
% of Revenue 54.73 50.29 46.38 43.76 39.00 39.59 41.54 41.65 40.53 39.88 39.74 38.21 38.04 39.44 38.59 38.54 39.19 38.66 38.48 42.05
SG&A 800 882 686 655 623 606 649 643 654 646 664 680 678 703 730 788 813 842 882 860
Change (%) 10.21 -22.22 -4.56 -4.85 -2.72 7.00 -0.85 1.77 -1.37 2.81 2.47 -0.25 3.63 3.82 7.92 3.18 3.58 4.82 -2.57
% of Revenue 17.08 19.96 15.25 15.47 14.08 12.10 11.59 10.75 10.29 10.18 9.97 9.47 9.03 8.66 8.91 8.94 8.98 9.34 9.57 10.11
R&D
Change (%)
% of Revenue
OpEx 5,758 5,393 5,006 4,821 4,999 5,307 5,934 6,210 6,495 6,362 6,369 6,652 6,833 7,235 7,417 7,936 8,113 8,164 8,390 7,863
Change (%) -6.34 -7.19 -3.68 3.69 6.16 11.82 4.63 4.59 -2.04 0.11 4.45 2.72 5.88 2.52 6.99 2.23 0.63 2.76 -6.27
% of Revenue 122.86 122.01 111.22 113.92 113.00 105.94 106.06 103.80 102.16 100.33 95.65 92.67 90.95 89.08 90.53 90.10 89.67 90.56 91.00 92.46
Operating Income -1,071 -973 -505 -589 -575 -297 -339 -227 -137 -21 290 526 680 887 776 872 935 851 830 641
Change (%) -9.19 -48.10 16.68 -2.38 -48.29 13.96 -32.96 -39.67 -84.86 -1,496.63 81.45 29.30 30.35 -12.45 12.38 7.14 -8.94 -2.54 -22.72
% of Revenue -22.86 -22.01 -11.22 -13.92 -13.00 -5.94 -6.06 -3.80 -2.16 -0.33 4.35 7.33 9.05 10.92 9.47 9.90 10.33 9.44 9.00 7.54
Interest Expense -310 -402 -513 -486 -452 -394 -320 -290 -283 -292 -322 -299 -245 -204 -164 -143 -138 -141 -145 -143
Change (%) 29.85 27.60 -5.27 -7.07 -12.73 -18.83 -9.49 -2.32 3.18 10.36 -7.12 -18.10 -16.87 -19.74 -12.52 -3.32 1.83 3.23 -1.66
% of Revenue -6.61 -9.10 -11.41 -11.49 -10.22 -7.87 -5.72 -4.84 -4.45 -4.60 -4.84 -4.17 -3.26 -2.51 -2.00 -1.62 -1.53 -1.56 -1.58 -1.68
Net Income -1,136 -1,307 -1,165 -1,248 -510 -201 -20 139 -409 -194 463 707 959 1,178 922 1,121 1,195 1,109 997 852
Change (%) 14.99 -10.82 7.07 -59.16 -60.57 -90.29 -814.39 -393.12 -52.50 -338.66 52.72 35.62 22.77 -21.75 21.64 6.63 -7.24 -10.13 -14.49
% of Revenue -24.24 -29.56 -25.89 -29.48 -11.52 -4.01 -0.35 2.33 -6.43 -3.06 6.96 9.85 12.77 14.50 11.25 12.73 13.21 12.30 10.81 10.02

Source: Capital IQ

Other Listings
IN:524372
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista